cphi-onlineMay 25, 2017
Tag: cell arteritis , Genentech
Genentech, a member of the Roche Group has announced that the FDA has approved Actemra (tocilizumab) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition. Actemra is the first therapy approved by the FDA for the treatment of adult patients with GCA. This is the sixth FDA approval for Actemra since the medicine was launched in 2010.
"Today’s FDA decision means people living with giant cell arteritis will, for the first time, have an FDA-approved treatment option for this debilitating disease," said Sandra Horning, chief medical officer and head of Global Product Development. "With no new treatments in more than 50 years, this approval could be transformational for people with GCA and for their physicians."
The approval is based on the positive outcome of the Phase III GiACTA study evaluating Actemra in patients with GCA. The results showed that Actemra, initially combined with a six-month steroid (glucocorticoid) regimen, more effectively sustained remission through 52 weeks (56% in the Actemra weekly group and 53.1% in the Actemra bi-weekly group) compared to placebo combined with a 26-week steroid taper (14%) and placebo combined with a 52-week steroid taper (17.6%).
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: